文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

基于肺形态的急性呼吸窘迫综合征患者一年结局:LIVE试验的二次分析

One-year patient outcomes based on lung morphology in acute respiratory distress syndrome: secondary analysis of LIVE trial.
PubMed 文献 · Crit Care · 2022-06-04
一句话结论非局灶性ARDS一年死亡率高于局灶性(37% vs 24%,p=0.012),差异由前90天死亡驱动,90天后仅McCabe评分独立相关。

本文为LIVE试验(前瞻性随机对照试验,评估按肺形态个体化通气设置在中重度ARDS中的价值)的二次分析,纳入124例局灶性ARDS与236例非局灶性ARDS患者。随访1年,非局灶性ARDS的一年死亡率高于局灶性(37% vs 24%,p=0.012);非局灶性ARDS(HR 3.44,95%CI 1.80-6.59,p<0.001)、年龄、McCabe评分、血液系统肿瘤、SAPS II、肾脏替代治疗与一年死亡率独立相关。该差异由前90天死亡驱动(28% vs 16%,p=0.010),90天至1年无差异(7% vs 6%,p=0.591),此阶段仅McCabe评分独立相关。肺形态学表型对患者报告结局无影响。

要点

  • 非局灶性ARDS一年死亡率37%,高于局灶性24%(p=0.012),差异由前90天死亡驱动(28% vs 16%,p=0.010)。
  • 90天至1年死亡率两组无差异(非局灶7% vs 局灶6%,p=0.591),此阶段仅McCabe评分独立相关。
  • 非局灶性ARDS与一年死亡率独立相关(HR 3.44,95%CI 1.80-6.59,p<0.001)。
  • 年龄、McCabe评分、血液系统肿瘤、SAPS II、肾脏替代治疗亦独立关联一年死亡率(原文未给各变量具体效应值)。
  • 肺形态学表型对患者报告结局无影响。

适用人群与场景

  • LIVE试验纳入的中重度ARDS患者,二次分析共124例局灶性ARDS与236例非局灶性ARDS。

诊断标准与关键阈值

  • ARDS按肺形态分为局灶性(实变仅位于下肺后部)或非局灶性。

研究设计与关键结果

  • 研究类型:LIVE试验(前瞻性随机对照试验,评估按肺形态个体化通气设置在中重度ARDS中的价值)的二次分析;共124例局灶性ARDS与236例非局灶性ARDS。
  • 一年死亡率:非局灶性ARDS 37% vs 局灶性24%(p=0.012)。
  • 一年死亡率独立相关因素:非局灶性ARDS(HR 3.44,95%CI 1.80-6.59,p<0.001)、年龄、McCabe评分、血液系统肿瘤、SAPS II、肾脏替代治疗。
  • 前90天死亡率:非局灶性28% vs 局灶性16%(p=0.010);90天至1年死亡率:非局灶性7% vs 局灶性6%(p=0.591),此阶段仅McCabe评分独立相关。
  • 肺形态学表型对患者报告结局无影响。

证据类型、等级与局限

  • 证据类型:前瞻性随机对照试验的二次分析。
  • 试验注册:NCT02149589;2014年5月29日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为:肺形态反映ARDS急性期及其短期影响,但不反映长期结局,长期结局似乎仅受合并症影响。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute respiratory distress syndrome (ARDS) has different phenotypes and distinct short-term outcomes. Patients with non-focal ARDS have a higher short-term mortality than focal ones. The aim of this study was to assess the impact of the morphological phenotypes of ARDS on long-term outcomes.

METHODS: This was a secondary analysis of the LIVE study, a prospective, randomised control trial, assessing the usefulness of a personalised ventilator setting according to lung morphology in moderate-to-severe ARDS. ARDS was classified as focal (consolidations only in the infero-posterior part of the lungs) or non-focal. Outcomes were assessed using mortality and functional scores for quality of life at the 1-year follow-up.

RESULTS: A total of 124 focal ARDS and 236 non-focal ARDS cases were included. The 1-year mortality was higher for non-focal ARDS than for focal ARDS (37% vs. 24%, p = 0.012). Non-focal ARDS (hazard ratio, 3.44; 95% confidence interval, 1.80-6.59; p < 0.001), age, McCabe score, haematological cancers, SAPS II, and renal replacement therapy were independently associated with 1-year mortality. This difference was driven by mortality during the first 90 days (28 vs. 16%, p = 0.010) but not between 90 days and 1 year (7 vs. 6%, p = 0.591), at which point only the McCabe score was independently associated with mortality. Morphological phenotypes had no impact on patient-reported outcomes.

CONCLUSION: Lung morphologies reflect the acute phase of ARDS and its short-term impact but not long-term outcomes, which seem only influenced by comorbidities.

TRIAL REGISTRATION: NCT02149589; May 29, 2014.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Blanchard F, Godet T, Pons S, et al. One-year patient outcomes based on lung morphology in acute respiratory distress syndrome: secondary analysis of LIVE trial. Crit Care. 2022. PMID: 35659328. doi:10.1186/s13054-022-04036-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。